Published in Antimicrob Agents Chemother on October 27, 2014
MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model. Antimicrob Agents Chemother (2015) 0.86
Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice. PLoS One (2016) 0.81
Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo. Virulence (2016) 0.80
EssE promotes Staphylococcus aureus ESS-dependent protein secretion to modify host immune responses during infection. J Bacteriol (2016) 0.79
Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opin Investig Drugs (2015) 0.79
Prevention and treatment of Staphylococcus aureus biofilms. Expert Rev Anti Infect Ther (2015) 0.79
Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother (2016) 0.77
Virulence determinants associated with the Asian community-associated methicillin-resistant Staphylococcus aureus lineage ST59. Sci Rep (2016) 0.77
Targeting surface protein SasX by active and passive vaccination to reduce Staphylococcus aureus colonization and infection. Infect Immun (2015) 0.76
A new approach to toxin neutralization in Staphylococcus aureus therapy. EMBO Rep (2016) 0.75
The role of genetics and antibodies in sepsis. Ann Transl Med (2016) 0.75
α-Toxin Regulates Local Granulocyte Expansion from Hematopoietic Stem and Progenitor Cells in Staphylococcus aureus-Infected Wounds. J Immunol (2017) 0.75
Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol (2005) 4.53
Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis (2010) 4.19
Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med (2008) 4.01
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis (2002) 3.80
Differential roles of macrophages in diverse phases of skin repair. J Immunol (2010) 3.56
IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest (2010) 3.40
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother (2005) 2.34
Perivascular macrophages mediate neutrophil recruitment during bacterial skin infection. Nat Immunol (2013) 2.22
Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol (2011) 2.20
Inflammation and wound healing: the role of the macrophage. Expert Rev Mol Med (2011) 2.13
Complicated skin and soft tissue infection. J Antimicrob Chemother (2010) 2.12
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
Macrophages in skin injury and repair. Immunobiology (2011) 2.00
Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel) (2013) 1.99
Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother (2011) 1.70
Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect Immun (2000) 1.65
Expression of an antisense hla fragment in Staphylococcus aureus reduces alpha-toxin production in vitro and attenuates lethal activity in a murine model. Infect Immun (1997) 1.56
Neutrophil-derived IL-1β is sufficient for abscess formation in immunity against Staphylococcus aureus in mice. PLoS Pathog (2012) 1.52
Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion. Microb Drug Resist (2011) 1.44
Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection. J Invest Dermatol (2012) 1.41
A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis (2013) 1.33
Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol (2012) 1.33
Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis (2013) 1.32
Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother (2013) 1.25
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother (2013) 1.24
Neutrophil survival and c-kit(+)-progenitor proliferation in Staphylococcus aureus-infected skin wounds promote resolution. Blood (2011) 1.22
Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05. Antimicrob Agents Chemother (2011) 1.21
Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother (2012) 1.09
Genomic analysis of the emergence of vancomycin-resistant Staphylococcus aureus. MBio (2012) 1.06
Tissue-specific patterning of host innate immune responses by Staphylococcus aureus α-toxin. J Innate Immun (2014) 1.06
Staphylococcus aureus alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model. PLoS One (2013) 1.06
Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis (2013) 1.01
Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PLoS One (2013) 0.99
Targeting Staphylococcus aureus α-toxin as a novel approach to reduce severity of recurrent skin and soft-tissue infections. J Infect Dis (2014) 0.98
Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem (2014) 0.98
Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res (2010) 0.93
Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med (2013) 0.92
In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob Agents Chemother (2009) 0.88
Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia. J Clin Microbiol (2014) 0.87
Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. J Antimicrob Chemother (2013) 0.84
Worrisome trend of new multiple mechanisms of linezolid resistance in staphylococcal clones diffused in Italy. J Clin Microbiol (2013) 0.82
Developments in skin and soft tissue infection. Curr Opin Infect Dis (2014) 0.77
Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease. MBio (2015) 0.89
Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother (2016) 0.77
Targeting Alpha Toxin to Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia. Antimicrob Agents Chemother (2017) 0.75